Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이경은 | * |
dc.date.accessioned | 2023-07-31T16:31:22Z | - |
dc.date.available | 2023-07-31T16:31:22Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 2005-9256 | * |
dc.identifier.other | OAK-33451 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/265389 | - |
dc.description.abstract | PURPOSE: This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer. Materials and Methods: Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient's body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events. RESULTS: A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2-positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%). CONCLUSION: This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes. | * |
dc.language | English | * |
dc.publisher | NLM (Medline) | * |
dc.subject | Breast neoplasms | * |
dc.subject | Drug therapy | * |
dc.subject | Oxaliplatin | * |
dc.subject | Phase II trial | * |
dc.subject | S-1 | * |
dc.title | A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 55 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 523 | * |
dc.relation.lastpage | 530 | * |
dc.relation.journaltitle | Cancer research and treatment | * |
dc.identifier.doi | 10.4143/crt.2022.1360 | * |
dc.identifier.wosid | WOS:000981654700016 | * |
dc.identifier.scopusid | 2-s2.0-85152477725 | * |
dc.author.google | Lee D.-W. | * |
dc.author.google | Keam B. | * |
dc.author.google | Lee K.S. | * |
dc.author.google | Ahn J.-H. | * |
dc.author.google | Sohn J. | * |
dc.author.google | Ahn J.S. | * |
dc.author.google | Lee M.H. | * |
dc.author.google | Kim J.H. | * |
dc.author.google | Lee K.E. | * |
dc.author.google | Kim H.J. | * |
dc.author.google | Kim S.-Y. | * |
dc.author.google | Park Y.H. | * |
dc.author.google | Ock C.-Y. | * |
dc.author.google | Lee K.-H. | * |
dc.author.google | Han S.-W. | * |
dc.author.google | Kim S.-B. | * |
dc.author.google | Im Y.H. | * |
dc.author.google | Chung H.C. | * |
dc.author.google | Oh D.-Y. | * |
dc.author.google | Im S.-A. | * |
dc.contributor.scopusid | 이경은(7501517217;58364338700) | * |
dc.date.modifydate | 20240123091958 | * |